Sorrento to Take Action Against Hindenburg Research for Statements Believed Intended to Manipulate Stock Price
August 12, 2020 19:51 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that it believes it has uncovered fraudulent attempts to manipulate the Company’s...
SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS
April 02, 2020 12:33 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren,...
Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program
March 25, 2020 10:00 ET
|
Sorrento Therapeutics, Inc.
STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virusThe I-Cell vaccine is...
SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19
March 23, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO and BOSTON, March 23, 2020 (GLOBE NEWSWIRE) -- In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and...
SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)
March 20, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
COVIDTRAPTM is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting...
Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference
February 27, 2020 06:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will present at the 9th Annual LEERINK...
Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference
February 21, 2020 09:15 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will present at LEERINK Partners 9th Annual Global Healthcare Conference...
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
January 29, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO and WARREN, N.J., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initated a clinical and manufacturing collaboration with...
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
January 27, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...
Sorrento Board Rejects Latest Acquisition Proposal
January 27, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
The latest non-binding proposal received on January 9, 2020 from a private equity fund to acquire a majority or all of the issued and outstanding shares of the company for “up to $7.00” per share...